Healio

FDA approves Vabysmo for treatment of wet AMD, DME

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Vabysmo for the treatment of wet age-related macular degeneration and diabetic macular ...
Healio

Vabysmo improves vision, reduces retinal fluid in phase 3 retinal vein occlusion studies

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Vabysmo met the primary endpoint of noninferior visual ...
Monthly Prescribing Reference

Vabysmo Approved for Macular Edema Following Retinal Vein Occlusion

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...
FiercePharma

Roche's Vabysmo looks to escalate Eylea fight as FDA takes up review in retinal vein occlusion

As Roche's Vabysmo takes a bite out of Regeneron's Eylea sales, the drug has moved one step closer toward an approval in another of its rival drug's uses. The FDA accepted Roche's Vabysmo application ...
Business Insider

Genentech's Vabysmo Shows Sustained Benefits In Long-Term Studies For Retinal Vein Occlusion

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that new long-term data for the company's Vabysmo showed sustained retinal drying and vision improvements in Retinal Vein Occlusion.
Business Wire

FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...
Nasdaq

RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress

Roche (RHHBY) announced new data from two studies on ophthalmology drug Vabysmo (faricimab). Vabysmo is already approved in several countries for people with neovascular or ‘wet’ age-related macular ...
FiercePharma

Roche scores FDA nod for prefilled syringe version of Vabysmo, easing its administration

Since Roche gained approval for its eye disease medication Vabysmo in 2022, it has stormed a market dominated by Regeneron and Bayer’s Eylea. Friday, Roche took another step in its advancement of the ...
Yahoo Finance

New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)

– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...
Nasdaq

FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

– Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive wet age-related macular degeneration (AMD) and diabetic macular edema (DME) – – Vabysmo is the only injectable eye ...
Yahoo Finance

New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)

In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end 1 Over 60% of ...